Theriva Biologics Inc (TOVX) — Titan Protect Analysis

TOVX

Theriva Biologics Inc

Healthcare · ·

$0.26

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$13M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.39

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-138.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$2.50

+862% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About Theriva Biologics Inc

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for trea

https://therivabio.com

Country: United States Employees: 15 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.323

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.2015

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.822

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-80.2%

Historical annualised return based on price data

Max Drawdown

-97.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.18

Moves slightly more than the broader market

52W High

$0.86

70% below the year high

52W Low

$0.16

62% above the year low

Avg Volume

21,033,431

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.58

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

23.98

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-709.0%

Profit from core operations before interest and tax

Free Cash Flow

$-4,870,250

Negative — the business is spending more than it generates

Revenue (TTM)

$300,000

Total revenue over the last 12 months

Net Income

$-22,969,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$4.00

Target Median

$2.50

Target Low

$1.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go